M. Mulheran

Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial

Alan R Smyth, Kelvin H-V Tan, Pauline Hyman‐Taylor et al. · The Lancet · 2005 · 225 citations

Pulmonary Care, Advanced Lung Disease, Pulmonary Exacerbations +6

Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy

M. Mulheran, Christopher Degg, S Burr et al. · Antimicrobial Agents and Chemotherapy · 2001 · 101 citations · Full text

Pediatric Otolaryngology, Auditory Deficit, Clinical Therapeutic +11

Comparison of Distortion Product OAE Generation between a Patient Group Requiring Frequent Gentamicin Therapy and Control Subjects

M. Mulheran, Christopher Degg · British Journal of Audiology · 1997 · 59 citations

Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients

M. Mulheran, Pauline Hyman‐Taylor, Kelvin H-V Tan et al. · Antimicrobial Agents and Chemotherapy · 2006 · 43 citations · Full text

Pediatric Otolaryngology, Cystic Fibrosis Patients, Audiology +8

Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis?the TOPIC study: a randomised controlled trial

Alan R Smyth, Kok Hian Tan, Pauline Hyman‐Taylor et al. · The Lancet · 2005 · 39 citations

Pulmonary Pharmacology, Pulmonary Fibrosis, Pulmonary Medicine +4